Resources

London Life Sciences Week kicked off last night with a buzzing reception at Somerset House and we’re looking forward to a jam-packed week of networking and events. Great to see the incredible hard work from the BIA and L&P teams come to life – shining a global light on the incredible UK ecosystem. At the same time, we’re seeing the UK take a leading role in pro-innovation regulation, from last week’s enactment of the Precision Breeding Act to Lawrence Tallon’s insights on the MHRA’s proportionate, strategic future approach, and now need the government to invest in the sector and ensure the commercial environment enables the UK to build on this world-beating foundation.

The Medical Research Council, Wellcome Trust, and Innovate UK have today announced a major new £15.9m initiative to enable the development of advanced, specific and highly reproducible human-based in vitro models of disease, to make them widely available to researchers in academia and industry.

​​​​​​​LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.

BIA and Japan Bioindustry Association signed an MOU, agreeing to work together to connect the two countries’ life sciences and biotech ecosystems to accelerate medical innovation and the commercialisation of engineering biology.

MORF-Bio is delighted to announce the successful closing of its pre-seed funding round to accelerate development of its microbial bioinformatics software.

In this blog, Tom Sheldon, Senior Manager at the Science Media Centre (SMC), explores how scientists and communicators are taking on misinformation head-on — and how the SMC’s work supports both researchers and journalists in helping the public make sense of complex, and sometimes controversial, scientific issues.

PACE (Pathways to Antimicrobial Clinical Efficacy) launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health.

Kirsty Neilson, Programme Manager at IBioIC, explains why she has just launched a new programme – Biotech Innovators: Train to Scale – offering a specialist business support programme for budding bioentrepreneurs.

The new kit is designed for use with the company’s Amperia™ benchtop platform and complements the existing Protein A-based format, enabling researchers to quantify a broader range of antibody isotypes and species using the same protocol-guided, user-friendly workflow and highly sensitive electrochemical readout.

Abzena has announced the expansion of our AbZelectPRO™ cell line development (CLD) platform with the launch of two next-gen Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

MDC and King’s College London have been awarded £400,000 funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

In a shifting global landscape, we break down how the UK's new Trade and National Security strategies aim to future-proof our biotech sector.

We're pleased to announce the appointment of Livija Deban, Chief Scientific Officer at Prokarium, as Chair of its Engineering Biology Advisory Committee (EBAC).

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, shares insights from the BIA's first-of-its-kind funding and investment analysis into UK Deep Biotech.

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.